0 results for 'Sanofi SA'
Generic Drug Maker Launches Plavix Clone
Shares of Bristol-Myers Squibb sank Tuesday as generic drug maker Apotex disclosed it has begun selling a cheaper version of the pharmaceutical company's drug Plavix. Bristol-Myers and its partner Sanofi-Aventis, which sells Plavix abroad, say their patent has been infringed. The recent focus on generic Plavix began in late July when Bristol-Myers and Sanofi-Aventis announced the Justice Department had launched a criminal probe into an out-of-court settlement they had brokered with Apotex.Drug Makers Delay Generics Hitting Market
The marketers of the world's second-largest-selling drug dodged a major threat to their revenues by reaching a deal to keep a generic competitor at bay until at least 2011. Now, 10 lawsuits have been filed over the settlement Sanofi-Aventis SA and Bristol-Myers Squibb reached with Apotex, a generic manufacturer challenging blood thinner Plavix's patent. The suits, filed by businesses, unions and health plans, allege the deal violates antitrust laws by denying access to cheap, generic versions of Plavix.Drug Makers Delay Generics Hitting Market
The marketers of the world's second-largest-selling drug dodged a major threat to their revenues by reaching a deal to keep a generic competitor at bay until at least 2011. Now, 10 lawsuits have been filed over the settlement Sanofi-Aventis SA and Bristol-Myers Squibb reached with Apotex, a generic manufacturer challenging blood thinner Plavix's patent. The suits, filed by businesses, unions and health plans, allege the deal violates antitrust laws by denying access to cheap, generic versions of Plavix.Stocks dip as investors enter week cautiously
Stocks edged lower today as investors took a cautious approach to trading before the government's latest report on the jobs market.In re Sanofi-Aventis Securities Litigation
Material Omission, Scienter Not Shown in Fraud Suit Stemming From FDA Denial of Anti-Obesity DrugLower Courts Follow Matrixx's Guidance on Motions to Dismiss
Last March, in the securities class action Matrixx Initiatives v. Siracusano, the U.S. Supreme Court unanimously rejected the defendants' proposed bright-line "statistically significant" rule for determining whether adverse event reports withheld from a pharmaceutical company's public filings are material as a matter of law.Trending Stories
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
Strong & Hanni Solves Storage Woes--Learn How You Can, Too
Brought to you by Filevine
Download Now
Meeting the Requirements of California's SB 553: Workplace Violence Prevention
Brought to you by NAVEX Global
Download Now
The Benefits of Outsourcing Beneficial Ownership Information Filing
Brought to you by Wolters Kluwer
Download Now
The Top 10 AI Use Cases in Private Equity
Brought to you by Ontra
Download Now